Brandt U, Schägger H, von Jagow G
Institut für Physikalische Biochemie, Universität München, Federal Republic of Germany.
Eur J Biochem. 1988 May 2;173(3):499-506. doi: 10.1111/j.1432-1033.1988.tb14026.x.
The three E-beta-methoxyacrylate (MOA) inhibitors oudemansin A, strobilurin A and MOA stilbene [3-methoxy-2(2-styrylphenyl)propenic acid-methylester], which differ by more than one order of magnitude in their binding affinity to the mitochondrial ubihydroquinone:cytochrome c oxidoreductase (bc1 complex), bind to a site that is not identical to the binding site for ubihydroquinone, the substrate of the outer ubiquinone reaction site (Qo centre). Although the ubihydroquinone molecule is still bound in the presence of the MOA inhibitors, its electrons cannot be transferred to the iron-sulfur centre. A shift of the relative position of the ubihydroquinone molecule in the reaction centre due to a conformational distortion of cytochrome b induced by the binding of the MOA inhibitor seems to be the reason for the blocked electron transfer. Further analysis shows that ubihydroquinone affects the Kd values of all three MOA inhibitors tested: the values are raised by a constant factor of two, although the inhibitors bind with quite different affinity. The iron-sulfur protein is not involved in the binding of the MOA inhibitors. These results have direct implications for the proper use of MOA inhibitors in experiments designed to analyse the structure/mechanism relationship in cytochrome c reductase. In particular, point mutations recently described in MOA-inhibitor-resistant mutants can no longer be taken to affect necessarily the ubihydroquinone binding site.
三种E-β-甲氧基丙烯酸酯(MOA)抑制剂,即奥德曼辛A、嗜球果伞素A和MOA芪[3-甲氧基-2(2-苯乙烯基苯基)丙烯酸甲酯],它们与线粒体泛醇:细胞色素c氧化还原酶(bc1复合物)的结合亲和力相差一个多数量级以上,它们结合的位点与泛醇(外泛醌反应位点(Qo中心)的底物)的结合位点不同。尽管在MOA抑制剂存在的情况下泛醇分子仍能结合,但其电子无法转移到铁硫中心。由于MOA抑制剂结合诱导细胞色素b构象扭曲,导致泛醇分子在反应中心的相对位置发生移动,这似乎是电子传递受阻的原因。进一步分析表明,泛醇会影响所测试的所有三种MOA抑制剂的解离常数(Kd)值:尽管抑制剂的结合亲和力差异很大,但这些值均以恒定的两倍因子升高。铁硫蛋白不参与MOA抑制剂的结合。这些结果对于在旨在分析细胞色素c还原酶结构/机制关系的实验中正确使用MOA抑制剂具有直接影响。特别是,最近在MOA抑制剂抗性突变体中描述的点突变不再一定被认为会影响泛醇结合位点。